Upstream Bio Inc

UPB

Market cap $436M

– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of - 1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also provided strong efficacy data in new analyses , including reduction in nasal congestion score (NCS) by -0.96 (p < 0.0001) – WALTHAM, Mass., March 01, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented additional data from the Phase 2 VIBRANT clinical trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps (CRSwNP).

– New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be presented during the late-breaking poster session –

WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in March:

Upstream Bio Inc. (NASDAQ: UPB) shares are trading lower during Friday's session as the stock reacts to recent developments in its clinical trials.

Shares of Upstream Bio crashed Wednesday after the biotech's asthma drug succeeded in Phase 2 study, but with a more frequent dosing regimen.

The stock gave up its gains and is falling, probably on profit booking.

– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing –

– Webcast to be held Wednesday, February 11, 2026, at 8:00 a.m. ET – – Webcast to be held Wednesday, February 11, 2026, at 8:00 a.m. ET –

WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 2:15 p.m. PT.

Upstream Bio, Inc. achieved statistical significance in the phase 2 VIBRANT trial for Verekitug in treating patients with CRSwNP, supporting a Buy rating. Verekitug's once-every-12-weeks dosing offers competitive differentiation versus standard of care and existing biologics like Tezspire. Upcoming UPB catalysts includes phase 2 VALIANT data in severe asthma expected in Q1 of 2026.